Multicenter study of phase II with Rituximab, cyclophosphamide, doxorubicin liposomal (Myocet), vincristine, Prednisone, (R-COMP) in diffuse Non-Hodgkin`s lymphoma, large B cells of the cardiopathic patient - HEART01

IIL INTERGRUPPO ITALIANO LINFOMI ONLUS0 个研究点目标入组 50 人开始时间: 2009年8月11日最近更新: 2017年1月31日

适应症

试验速览

暂无简介。

•1. NHL histological diagnosis of diffuse large B cell CD20 + (de novo or shift from low-grade NHL if not pretreated), grade IIIb follicular NHL; 2.Age >= 18 years; 3.Presence of at least 1 factor that defines the cardiopathy(see Annex F); 4.Life expectancy > 3 months; 5.In the case of women of childbearing age absence of pregnancy at the beginning of the chemotherapy; 6.Written informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1.Histology different from NHL diffuse large cell CD20 + or follicular IIIb 2.Age < 18 years 3.Inability to sign informed consent; 4.HIV positivity; 5.Patients HBsAg positive; 6.AST / ALT > 2 times the standard; 7.Bilirubin > 2 times the standard; 8.Creatinina > 2.5 mg / dl; 9.Location of CNS disease; 10.Pregnancy ongoing; 11.Damage to that organ or medical problems that could interfere with the therapy; 12.Current uncontrolled infection; 13.Senile dementia

发起方

IIL INTERGRUPPO ITALIANO LINFOMI ONLUS